BackgroundCA125, a tumor-associated antigen, is primarily used to monitor epithelial ovarian cancer. There is evidence that different species of CA125 exist; however, it is not known if any of these species are present in healthy women during the menstrual cycle and if they are associated with serum concentrations of CA125. The purpose of this study was to determine if the molecular species of CA125 differ across the three phases of the menstrual cycle in healthy women.MethodsHealthy, Caucasian women between the ages of 18 and 39 were enrolled using strict criteria to exclude factors known to contribute to CA125 fluctuations. Menstrual cycle regularity was determined using calendars maintained by participants for 3 months. After cycle regul...
Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. Howev...
Abstract Background Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of car...
Since Bast et. al. reported that patients with ovarian carcinoma had elevated levels of CA125 in ser...
BackgroundCA125, a tumor-associated antigen, is primarily used to monitor epithelial ovarian cancer....
Background: CA125, a tumor-associated antigen, is primarily used to monitor epithelial ovarian cance...
ABSTRACTAn Evaluation of the Molecular Species of CA125 Across the Three Phases of the Menstrual Cyc...
BackgroundClinicians use CA125, a tumor-associated antigen, primarily to monitor epithelial ovarian ...
Background. Clinicians use CA125, a tumor-associated antigen, primarily tomonitor epithelial ovarian...
Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multipl...
CA-i 25 is a glycoprotein associated with various ovarian tumors. A commercial radioimmunoassay invo...
Background: Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to d...
4To whom correspondence should be addressed The aim of this study was to investigate cycle dependent...
No noninvasive diagnostic tests reliably discriminate endome-triosis and other pelvic pain-causing d...
PurposeCancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal ...
3To whom correspondence should be addressed Cancer antigen 125 (CA125) is an antigenic determinant d...
Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. Howev...
Abstract Background Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of car...
Since Bast et. al. reported that patients with ovarian carcinoma had elevated levels of CA125 in ser...
BackgroundCA125, a tumor-associated antigen, is primarily used to monitor epithelial ovarian cancer....
Background: CA125, a tumor-associated antigen, is primarily used to monitor epithelial ovarian cance...
ABSTRACTAn Evaluation of the Molecular Species of CA125 Across the Three Phases of the Menstrual Cyc...
BackgroundClinicians use CA125, a tumor-associated antigen, primarily to monitor epithelial ovarian ...
Background. Clinicians use CA125, a tumor-associated antigen, primarily tomonitor epithelial ovarian...
Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multipl...
CA-i 25 is a glycoprotein associated with various ovarian tumors. A commercial radioimmunoassay invo...
Background: Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to d...
4To whom correspondence should be addressed The aim of this study was to investigate cycle dependent...
No noninvasive diagnostic tests reliably discriminate endome-triosis and other pelvic pain-causing d...
PurposeCancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal ...
3To whom correspondence should be addressed Cancer antigen 125 (CA125) is an antigenic determinant d...
Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. Howev...
Abstract Background Ovarian cancer screening in BRCA1/2 mutation carriers utilizes assessment of car...
Since Bast et. al. reported that patients with ovarian carcinoma had elevated levels of CA125 in ser...